Elmar Schnee
Elmar Schnee
Chairman
VIEW BIO
Elmar Schnee
Elmar Schnee
Chairman

Born 1959. Board member since 2019.

Education: Master’s degree in marketing and management from SIB.

Board Committees: Chairman of the Remuneration Committee.

Experience: Elmar Schnee was previously CEO of Merck Serono and was instrumental in the acquisition of Serono by Merck KGaA. He has also served as General Partner and member of the Executive Board of Merck KGaA and has held previously several senior global management positions with UCB and Sanofi.

Other current assignments: Chairman of the board of directors of Santhera Pharmaceutical, ProCom Rx SA, Moleac Pte Lts, Noorik Biopharmaceuticals AG and Advanz Pharma as well a member of the board of directors of Jazz Pharmaceuticals, Kuste Biopharma and Damian Pharma AG.

Holdings in the Company: Elmar Schnee holds 23,236 share awards in board LTIP 2019 and 14,063 share awards in LTIP 2020.

Independent in relation to the Company and its management and in relation to major shareholders.

Chairman of the Board
Chair of the Remuneration Committee
Member of the Board of Directors
Member of the Remuneration Committee
Member of the Nomination Committee
Hilde Furberg
Hilde Furberg
Non-executive Director
VIEW BIO
Hilde Furberg
Hilde Furberg
Non-executive Director

Born 1958. Board member since 2014.

Education: Master of Science in Engineering from Oslo University, Norway.

Board Committees: Member of the Audit Committee.

Experience: Hilde Furberg is an independent consultant and professional Board member. She has extensive experience of leadership from her 35 years in sales, marketing, strategy and management in Pharma / Biotech. Her experience is in various fields of rare diseases, which she gained working in small companies and large global corporations. Hilde has worked in companies such as Genzyme and Baxter, she was most recently SVP and General Manger / European Head of Rare Diseases at Sanofi Genzyme. In addition to working for Genzyme / Sanofi Genzyme, Hilde has since 2005 worked as non-executive director and Board member of Probi, Pronova, Clavis, Bergenbio and Algeta.

Other current assignments: She is currently an industrial advisor to Investinor and Board member of Tappin and PCI Biotech.

Holdings in the company:Hilde Furberg holds 44,750 shares in the company, 8,449 share awards in board LTIP 2019 and 4,327 share awards in board LTIP 2020.

Independent in relation to the Company and its management and in relation to major shareholders.

Member of the Board of Directors
Member of the Audit Committee
Lennart Hansson
Lennart Hansson
Non-executive Director
VIEW BIO
Lennart Hansson
Lennart Hansson
Non-executive Director

Born 1956. Board member since 2009.

Education: PhD in Genetics from the University of Umeå.

Experience: Lennart Hansson has broad experience from leading positions within pharmaceutical development and business development in both biotech and pharma companies such as KabiGen AB, Symbicom AB, AstraZeneca, Biovitrum AB and as CEO of Arexis AB. Lennart was responsible for Industrifonden’s life science operations between 2008– 2016. He has worked on more than 30 company boards and is also the co-founder of two pharmaceutical development companies.

Other current assignments: Chairman of the Board of Directors of Sixera Pharma AB, Ignitus AB and Cinclus Pharma Holding AB. Member of the Board of Directors of InDex Pharmaceuticals Holding AB (publ), and Medivir AB (publ).

Holdings in the company: Lennart Hansson holds 12,000 shares in the company and 8,449 share awards in board LTIP 2019 and 4,327 share awards in board LTIP 2020.

Independent in relation to the Company and its management and in relation to major shareholders.

Member of the Board of Directors
Member of the Audit Committee
Member of the Remuneration Committee
Molly Henderson
Molly Henderson
Non-executive Director
VIEW BIO
Molly Henderson
Molly Henderson
Non-executive Director

Born 1970. Board member since 2020.

Education: M.B.A. and B.S. degree from the State University of New York at Buffalo.

Board Committees: Chairman and member of the Audit Committee.

Experience: Molly Henderson has served as the CFO of several listed life science companies for over 17 years. Currently, she is the CFO of UroGen Pharma, Inc. She was previously the CFO and Executive Vice President of Advaxis, Inc, the CFO of Iovance Biotherapeutics, Inc. (formerly Lion Biotechnologies, Inc.) and before that the Chief Business and Financial Officer and Senior Vice President of VirtualScopics, Inc. Molly has also advised start-up companies in Switzerland, and was a Manager in the audit division of PricewaterhouseCoopers LLP.

Other current assignments: CFO of UroGen Pharma, Inc.

Holdings in the Company: Molly Henderson holds 100 shares in the company and 4,327 share awards in board LTIP 2020

Independent in relation to the Company and its management and in relation to major shareholders.

Member of the Board of Directors
Chairman of the Audit Committee
Member of the Audit Committee
Diane Parks
Diane Parks
Non-executive Director
VIEW BIO
Diane Parks
Diane Parks
Non-executive Director

Born 1952. Board member since 2019.

Education: Master’s degree from Kansas State University and an MBA from Georgia State University.

Board Committees: Member of the Remuneration Committee.

Experience: Diane Parks is a senior executive with deep sales and marketing experience from the US, where she has held positions such as Head of US Commercial for Kite Pharma, VP of Sales for Amgen and Head of Global Marketing at Pharmacyclics.

Other current assignments: Board member in Kura Oncology, Soligenix and TriSalus Life Sciences.

Holdings in the Company: Diane Parks holds 8,449 share awards in board LTIP 2019 and 4,327 share awards in board LTIP 2020.

Independent in relation to the Company and its management and in relation to major shareholders.

Member of the Board of Directors
Member of the Remuneration Committee

Shareholding in the Company as of July 1, 2020.

* For more information on the incentive programs, see section “Governance – Remuneration”.